Physician profile
Jason Brenner
NPI 1750674719
$30,699.90
in general payments reported to CMS, 2019-2025
32 companies · $7,101 in 2025
The $7,101 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $564 · 2021: $746 · 2022: $2,670 · 2023: $8,347 · 2024: $10K · 2025: $7,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $6,254 · Travel and Lodging: $1,255 · Honoraria: $51.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,280.70 |
| Food and Beverage | $6,253.86 |
| Travel and Lodging | $1,255.10 |
| Honoraria | $51.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $22,372.93 | 2019-2025 | Wavelight Refractive Suite, Wavelight Ex500 Excimer Laser, Wavelight |
| Glaukos Corporation | $2,218.61 | 2019-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Abbvie INC. | $820.65 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Tarsus Pharmaceuticals, INC. | $672.10 | 2024-2025 | Xdemvy |
| Lensar, INC. | $650.00 | 2024 | Lensar Laser System |
| Novartis Pharmaceuticals Corporation | $501.87 | 2019-2023 | |
| Alcon Research LLC | $455.70 | 2023 | |
| Allergan, INC. | $314.26 | 2019-2022 | |
| Horizon Therapeutics Plc | $296.71 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $262.95 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $237.20 | 2019-2022 | |
| Rxsight INC | $233.64 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Dompe US, INC. | $191.37 | 2019-2025 | Oxervate |
| Eyepoint US, INC. | $173.12 | 2019 | |
| Oyster Point Pharma, INC. | $156.54 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $147.18 | 2022-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Lumenis Be INC | $143.50 | 2023 | M22 |
| Bausch & Lomb Americas INC. | $142.96 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Beaver-Visitec International, INC. | $127.60 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $121.03 | 2024 | |
| Aerie Pharmaceuticals, INC. | $117.32 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $60.65 | 2019 | |
| Optovue, INC. | $56.53 | 2020-2021 | |
| Amgen INC. | $52.92 | 2024 | Tepezza |
| Harrow Eye, LLC | $49.55 | 2024 | |
| Ani Pharmaceuticals, INC. | $30.36 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $25.55 | 2020 | |
| Thea Pharma INC. | $14.58 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $14.50 | 2023 | Tecnis Iol |
| Ocular Therapeutix, INC. | $13.62 | 2024 | Dextenza |
| Omeros Corporation | $12.47 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.